Ticker > Company >

Oxygenta Pharma share price

Oxygenta Pharmaceutical Ltd.

BSE: 524636 SECTOR: Pharmaceuticals & Drugs  12.08 K   4   1

71.65
-0.28 (-0.39%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 73.95

Today's Low

₹ 71.4

52 Week High

₹ 133.5

52 Week Low

₹ 37.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

264.99 Cr.

Enterprise Value

322.12 Cr.

No. of Shares

3.7 Cr.

P/E

0

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  -8.56

CASH

0.1 Cr.

DEBT

57.23 Cr.

Promoter Holding

57.92 %

EPS (TTM)

₹  -4.07

Sales Growth

27.93%

ROE

0 %

ROCE

-41.69%

Profit Growth

69.93 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year27.93%
3 Year-8.66%
5 Year14.09%

Profit Growth

1 Year69.93%
3 Year-205.9%
5 Year-1.42%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year-41.69%
3 Year-29.61%
5 Year-17.76%

Debt/Equity

-2.7669

Price to Cash Flow

-20.31

Interest Cover Ratio

-7.703

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 57.92 0.00
Mar 2025 51.12 0.00
Dec 2024 51.12 0.00
Sep 2024 53.28 0.00
Jun 2024 33.69 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -56.3234 days.
  • The company has a high promoter holding of 57.92%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 14.0347407185441.

 Limitations

  • The company has shown a poor profit growth of -205.896614174321% for the Past 3 years.
  • The company has shown a poor revenue growth of -8.66379343596417% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of -29.6063337278184% over the past 3 years
  • Company has negative cash flow from operations of -13.0496.
  • The company has a low EBITDA margin of -18.9921008274976% over the past 5 years.
  • The company has negative book value.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 12.62 14.75 33.21 49.47 15.14
Total Expenditure 14.41 16.18 37.56 51.15 21.97
Operating Profit -1.78 -1.42 -4.36 -1.68 -6.83
Other Income 0.02 0 0.49 0.05 0.17
Interest 0.41 0.69 0.39 2.13 0.63
Depreciation 0.65 0.66 0.71 -0.23 0.85
Exceptional Items 0 0 0 -0.27 -0.01
Profit Before Tax -2.82 -2.77 -4.96 -3.8 -8.15
Tax -1.45 0.08 -1.03 -1.65 -2.04
Profit After Tax -1.36 -2.86 -3.93 -2.15 -6.11
Adjusted EPS (Rs) -0.38 -0.8 -1.06 -0.58 -1.65

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 13.72 52.03 60.52 30.99 39.64
Total Expenditure 21.58 48.18 59.05 38.1 49.34
Operating Profit -7.87 3.84 1.48 -7.12 -9.7
Other Income 0.03 0.09 0 0.02 0.04
Interest 1.09 1.78 0.92 1.49 1.59
Depreciation 1 1.2 1.59 2.05 2.66
Exceptional Items 3.99 2.19 0.55 -0.73 0.04
Profit Before Tax -5.94 3.14 -0.49 -11.37 -13.87
Tax -0.15 0.21 0.12 0.2 -10.39
Net Profit -5.79 2.93 -0.61 -11.57 -3.48
Adjusted EPS (Rs.) -5.67 2.87 -0.43 -8.15 -1.04

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10.2 10.2 14.2 14.2 33.48
Total Reserves -51.15 -48.22 -48.83 -60.4 -53.61
Borrowings 25.44 45.04 51.04 62.25 49
Other N/C liabilities 18.28 9.35 6.69 5.31 -8.12
Current liabilities 15.85 17.5 8.07 32.9 33.7
Total Liabilities 18.62 33.86 31.18 54.26 54.46
Assets
Net Block 11.42 16.31 19.98 27.91 29.36
Capital WIP 0 0.65 0.34 0 0
Intangible WIP 0 0 0 0 0
Investments 0.05 0.05 0.05 0.05 0.05
Loans & Advances 0.38 0.91 1.24 1.3 0.95
Other N/C Assets 0 0 0 0 0
Current Assets 6.77 15.94 9.56 25.01 24.11
Total Assets 18.62 33.86 31.18 54.26 54.46
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -5.94 3.14 -0.49 -11.37 -13.87
Adjustment 2.07 2.96 2.51 3.53 4.31
Changes in Assets & Liabilities 1.13 -7.51 -3.58 6.2 -3.49
Tax Paid 0.15 -0.21 -0.12 0 0
Operating Cash Flow -2.59 -1.62 -1.68 -1.63 -13.05
Investing Cash Flow -0.5 -6.72 -4.94 -9.64 -4.09
Financing Cash Flow 3.19 8.67 6.33 11.22 17.13
Net Cash Flow 0.1 0.33 -0.29 -0.05 -0.01

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 33.69 53.28 51.12 51.12 57.92
jhansi rani vankineni 0.07 0.07 0.07 0.07 0.07
sai sudhakar vankineni 0.65 0.65 0.62 0.62 0.08
snigdha vankineni 3.22 3.22 3.09 3.09 1.47
sumanth simha vankineni 0.97 0.97 0.93 0.93 0.93
virupaksha organics limit... - - - - 55.37
aakanksha m chawda 4.46 4.46 4.28 4.28 -
amigos molecular solution... 0.56 0.56 0.54 0.54 -
m v s prasad reddy 4.79 26.64 25.56 25.56 -
manoj sunil chawda 4.46 4.46 4.28 4.28 -
rachamallu aparna 0.28 0.28 0.27 0.27 -
sadasiva reddy devagudi 0.24 0.24 0.23 0.23 -
sunil vishram chawda 11.73 11.73 11.25 11.25 -
k. raghavender rao 2.25 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 66.31 46.72 48.88 48.88 42.08
aakanksha m chawda - - - - 1.54
b subba reddy 1.32 1.32 1.26 1.26 1.26
devarapally venkateswara ... - - 2.70 2.70 2.70
kumuda katasani - 2.51 2.40 2.40 2.27
llp - - - - 0.01
manoj s. chawda - - - - 1.54
sanagari kondal reddy 1.41 1.41 1.35 1.35 1.35
satyanarayana reddy bandi... - - 1.35 1.35 1.35
sravani reddy gantla 12.65 12.65 12.13 12.13 6.78
sunil v. chawda - - - - 2.97
sandeep kumar reddy kommi... 7.77 7.77 7.45 7.45 -
subba reddy bhimavarapu 4.32 4.32 4.14 4.14 -
hemanth kumar kowdi 1.41 - - - -
kishore babu bathula 1.41 - - - -
pushpalatha vustala 8.45 - - - -
qemiq pharma private limi... 11.14 - - - -
srivani junoothula 1.07 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Oxygenta Pharma - Quaterly Results 14 Aug, 4:52 PM Oxygenta Pharma - Quaterly Results 14 Aug, 4:52 PM Oxygenta Pharmaceutical informs about disclosure 6 Jun, 5:27 PM Oxygenta Pharmaceutical informs about disclosure 2 Jun, 5:25 PM Oxygenta Pharma - Quaterly Results 30 May, 8:30 PM Oxygenta Pharmaceutical informs about disclosure 28 Apr, 3:44 PM Oxygenta Pharmaceutical informs about closure of trading window 31 Mar, 11:52 AM Oxygenta Pharmaceutical informs about RTA certificate 18 Oct, 2:56 PM Oxygenta Pharmaceutical informs about disclosure 3 Oct, 1:58 PM Oxygenta Pharmaceutical informs about disclosure 27 Sep, 2:49 PM Oxygenta Pharma - Quaterly Results 14 Aug, 8:29 PM Oxygenta Pharmaceutical informs about disclosure 18 Apr, 3:30 PM Oxygenta Pharmaceutical informs about closure of trading window 30 Mar, 12:54 PM Oxygenta Pharma - Quaterly Results 14 Feb, 8:46 PM Oxygenta Pharmaceutical informs about outcome of board meeting 14 Aug, 5:15 PM Oxygenta Pharmaceutical informs about disclosure 26 Jun, 3:00 PM Oxygenta Pharmaceutical informs about compliance certificate 4 May, 2:42 PM Oxygenta Pharmaceutical informs about certificate 28 Apr, 12:14 PM Oxygenta Pharmaceutical informs about disclosure 5 Jan, 4:21 PM Oxygenta Pharmaceutical informs about newspaper publication 22 Sep, 4:22 PM Oxygenta Pharma - Quaterly Results 20 May, 4:42 PM Oxygenta Pharma - Quaterly Results 20 May, 4:42 PM Oxygenta Pharma - Quaterly Results 20 May, 4:42 PM SS Organics informs about resignation of director 8 Dec, 12:03 PM SS Organics informs about certificate 27 Apr, 3:57 PM SS Organics submits AGM notice 8 Dec, 1:23 PM SS Organics informs about confirmation certificate 20 Oct, 1:53 PM

Oxygenta Pharma Stock Price Analysis and Quick Research Report. Is Oxygenta Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Oxygenta Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Oxygenta Pharma has a PE ratio of -17.6165420928403 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Oxygenta Pharma has ROA of -6.4003% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Oxygenta Pharma has a Current ratio of 0.7154.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Oxygenta Pharma has a ROE of 0%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Oxygenta Pharma has a Debt to Equity ratio of -2.7669 which means that the company has low proportion of debt in its capital.

  • Sales growth: Oxygenta Pharma has reported revenue growth of 27.9293% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Oxygenta Pharma for the current financial year is -24.4601068056435%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Oxygenta Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Oxygenta Pharma is Rs -4.0672. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Oxygenta Pharma in Ticker for free. Also, one can get the intrinsic value of Oxygenta Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Oxygenta Pharma FAQs

Q1. What is Oxygenta Pharma share price today?
Ans: The current share price of Oxygenta Pharma is Rs 71.65.

Q2. What is the market capitalisation of Oxygenta Pharma?
Ans: Oxygenta Pharma has a market capitalisation of Rs 264.9867775 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Oxygenta Pharma?
Ans: The PE ratio of Oxygenta Pharma is -17.6165420928403 and the P/B ratio of Oxygenta Pharma is -8.37512127269114, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Oxygenta Pharma share?
Ans: The 52-week high share price of Oxygenta Pharma is Rs 133.5, and the 52-week low share price of Oxygenta Pharma is Rs 37.5.

Q5. Does Oxygenta Pharma pay dividends?
Ans: Currently, Oxygenta Pharma does not pay dividends. Dividend yield of Oxygenta Pharma is around 0%.

Q6. What are the face value and book value of Oxygenta Pharma shares?
Ans: The face value of Oxygenta Pharma shares is Rs 10, while the book value per share of Oxygenta Pharma is around Rs -8.5551. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Oxygenta Pharma?
Ans: Oxygenta Pharma has a total debt of Rs 57.2337 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Oxygenta Pharma?
Ans: The ROE of Oxygenta Pharma is 0% and ROCE of Oxygenta Pharma is -41.687%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Oxygenta Pharma a good buy for the long term?
Ans: The Oxygenta Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Oxygenta Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Oxygenta Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Oxygenta Pharma’s financials?
Ans: You can review Oxygenta Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Oxygenta Pharma
X